Citius Oncology, Inc. (CTOR)

Over the past six months, Citius Oncology's stock has experienced significant events. The successful U.S. commercial launch of LYMPHIR in December 2025 led to an initial reported revenue of $3.9 million and a stock surge. The company completed strategic financings in December 2025 and May 2026 to support LYMPHIR's commercialization. In April 2026, Nasdaq notified Citius Oncology that its common stock bid price had fallen below the minimum $1.00 per share requirement. The company announced positive topline results from investigator-initiated Phase 1 studies evaluating LYMPHIR in combination with pembrolizumab in relapsed or refractory gynecologic cancers and prior to CAR-T therapy in high-risk diffuse large B-cell lymphoma.

There is no explicit information indicating demand seasonality for Citius Oncology's primary product, LYMPHIR. Demand is typically driven by disease incidence and diagnosis rather than seasonal factors. The company's management estimates the initial market for LYMPHIR to be growing and underserved, suggesting a consistent need for the therapy.

Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies. The company's primary product, LYMPHIR, received FDA approval in August 2024 for treating adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) and was commercially launched in the United States in December 2025. LYMPHIR is the first FDA-approved systemic therapy for CTCL in over seven years, addressing a growing U.S. market estimated to exceed $400 million.

Citius Oncology's primary commercial focus is the United States, where it has established nationwide specialty distribution agreements. The company is also pursuing international expansion, initiating its first European shipment of LYMPHIR and laying the groundwork for access in 19 markets across Southern Europe and the Middle East through distribution partners and Named Patient Programs.

Citius Oncology's brand reputation has been positively influenced by the FDA approval and commercial launch of LYMPHIR. Positive topline results from clinical trials evaluating LYMPHIR in combination with other cancer therapies have further enhanced its reputation. The company's efforts in establishing broad market access and its use of an AI-enabled commercial platform also contribute positively to its image. A Nasdaq non-compliance notice regarding its bid price is a regulatory concern but has not significantly impacted the brand's reputation.

Citius Pharmaceuticals Inc. is the largest individual shareholder, owning 74.34% of the company. Major institutional owners include Armistice Capital, Llc, Vanguard Group Inc, and BlackRock, Inc. Institutional investors collectively own 70.52% of Citius Oncology's stock.